EHA Library - The official digital education library of European Hematology Association (EHA)

A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION
Author(s): ,
Maria-Victoria Mateos
Affiliations:
Hospital Clinico Universitario de Salamanca,Salamanca,Spain
,
Katja Weisel
Affiliations:
University Medical Center Hamburg-Eppendorf,Hamburg,Germany
,
Valerio De Stefano
Affiliations:
Section of Hematology, Department of Radiological and Hematological Sciences,Catholic University, Fondazione Policlinico A. Gemelli, IRCCS,Roma,Italy
,
Aurore Perrot
Affiliations:
Institut Universitaire du Cancer de Toulouse-Oncopole,Toulouse,France
,
Niels van de Donk
Affiliations:
Amsterdam UMC, Vrije Universiteit Amsterdam,Amsterdam,Netherlands
,
Hartmut Goldschmidt
Affiliations:
University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germany
,
Martin Kaiser
Affiliations:
Institute of Cancer Research,London,United Kingdom
,
Ravi Vij
Affiliations:
Washington University School of Medicine,St. Louis,United States
,
Francesca Gay
Affiliations:
Division of Hematology,University of Torino,Torino,Italy
,
Annemiek Broijl
Affiliations:
Department of Hematology,Erasmus MC Cancer Institute,Rotterdam,Netherlands
,
Anna Potamianou
Affiliations:
Janssen-Cilag,Neuss,Germany
,
Caline Sakabedoyan
Affiliations:
EMEA Medical Affairs,Janssen-Cilag,Beirut,Lebanon
,
Vadim Strulev
Affiliations:
EMEA Medical Affairs,Janssen Pharmaceutica NV,Beerse,Belgium
,
Jordan Schecter
Affiliations:
Janssen R&D,Raritan,United States
,
Martin Vogel
Affiliations:
Janssen Global Services, LLC,Raritan,United States
,
Tonia Nesheiwat
Affiliations:
Medical Affairs,Legend Biotech USA Inc,Piscataway,United States
,
Robert Wapenaar
Affiliations:
Janssen-Cilag BV,Breda,Netherlands
,
Michel Delforge
Affiliations:
Department of Hematology,University Hospitals (UZ) Leuven,Leuven,Belgium
,
Hermann Einsele
Affiliations:
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II,Wuerzburg,Germany
Philippe Moreau
Affiliations:
Clinical Hematology,University Hospital Hotel-Dieu,Nantes,France
EHA Library. Mateos M. 06/09/21; 325745; EP987
Dr. María-Victoria Mateos
Dr. María-Victoria Mateos
Contributions
Abstract
Presentation during EHA2021: All Oral presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP987

Type: E-Poster Presentation

Session title: Myeloma and other monoclonal gammopathies - Clinical

Background
Despite advances in medical treatments that have improved patient survival, multiple myeloma (MM) remains an incurable disease. Most patients with MM eventually progress through standard drug classes of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), anti-CD38 monoclonal antibodies (mAbs), and others. There are currently no prospective data on real-world standard of care in patients who progress after PIs, IMiDs, and anti-CD38 mAbs.

Aims
To describe the interim results from LocoMMotion (NCT04035226), the first prospective study on the efficacy and safety of real-life standard of care in patients with relapsed/refractory MM.

Methods
Between August 2019 and October 2020, eligible patients who were aged ≥18 years and had a diagnosis of MM were enrolled in 75 sites across 9 European countries and the US. Patients were included if they had received 3 or more prior lines of therapy or were double-refractory to a PI and IMiD, had measurable disease at screening, received at least a PI, an IMiD, and anti-CD38 mAb with documented progressive disease since their last line of therapy, and had an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. All patients provided informed consent prior to enrollment in the study. Responses were assessed per International Myeloma Working Group response criteria. The overall response rate (ORR) of real-life current standard of care (primary objective of the study) was assessed by a Response Review Committee. Secondary objectives of the study included additional efficacy and safety evaluation of real-life standard of care.

Results
The data cut-off was November 4, 2020 for the first interim analysis of 225 patients (203 [90.2%] from Europe and 22 [9.8%] from the US) with a median follow-up of 3.7 months (range: 0–12.7). The median age was 68 years (range: 41–89), 124 (55.1%) patients were male, 162 (72.0%) had a baseline ECOG PS score of 1, and median time since initial MM diagnosis was 6.0 years (range: 0.3–22.8). Patients had received a median of 4.0 (range: 2–13) prior lines of therapy; all patients were triple-class exposed, 166 (73.8%) were triple-class refractory, and 208 (92.4%) were refractory to their last line of therapy. The ORR with real-life standard of care salvage therapy was 20.1% (95% CI: 15.0–26.0) in the response-evaluable population (n=219). Treatment-emergent adverse events (TEAEs) were reported in 148 (65.8%) patients, 95 (42.2%) were grade 3 or higher. The most common grade ≥3 TEAEs were anemia, thrombocytopenia, and neutropenia. Fifteen deaths (6.7%) occurred due to TEAEs during the study. Treatment is ongoing in 121 (53.8%) patients.

Conclusion
The interim results of this first, prospective study of real-life standard of care treatment demonstrate that heavily pretreated, triple-class exposed patients with relapsed/refractory MM continue to progress after multiple lines of therapy and have poor outcomes. Therefore, new treatments with novel mechanisms of action are needed for this patient population.

Keyword(s): Multiple myeloma, Refractory, Relapse, Treatment

Presentation during EHA2021: All Oral presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP987

Type: E-Poster Presentation

Session title: Myeloma and other monoclonal gammopathies - Clinical

Background
Despite advances in medical treatments that have improved patient survival, multiple myeloma (MM) remains an incurable disease. Most patients with MM eventually progress through standard drug classes of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), anti-CD38 monoclonal antibodies (mAbs), and others. There are currently no prospective data on real-world standard of care in patients who progress after PIs, IMiDs, and anti-CD38 mAbs.

Aims
To describe the interim results from LocoMMotion (NCT04035226), the first prospective study on the efficacy and safety of real-life standard of care in patients with relapsed/refractory MM.

Methods
Between August 2019 and October 2020, eligible patients who were aged ≥18 years and had a diagnosis of MM were enrolled in 75 sites across 9 European countries and the US. Patients were included if they had received 3 or more prior lines of therapy or were double-refractory to a PI and IMiD, had measurable disease at screening, received at least a PI, an IMiD, and anti-CD38 mAb with documented progressive disease since their last line of therapy, and had an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. All patients provided informed consent prior to enrollment in the study. Responses were assessed per International Myeloma Working Group response criteria. The overall response rate (ORR) of real-life current standard of care (primary objective of the study) was assessed by a Response Review Committee. Secondary objectives of the study included additional efficacy and safety evaluation of real-life standard of care.

Results
The data cut-off was November 4, 2020 for the first interim analysis of 225 patients (203 [90.2%] from Europe and 22 [9.8%] from the US) with a median follow-up of 3.7 months (range: 0–12.7). The median age was 68 years (range: 41–89), 124 (55.1%) patients were male, 162 (72.0%) had a baseline ECOG PS score of 1, and median time since initial MM diagnosis was 6.0 years (range: 0.3–22.8). Patients had received a median of 4.0 (range: 2–13) prior lines of therapy; all patients were triple-class exposed, 166 (73.8%) were triple-class refractory, and 208 (92.4%) were refractory to their last line of therapy. The ORR with real-life standard of care salvage therapy was 20.1% (95% CI: 15.0–26.0) in the response-evaluable population (n=219). Treatment-emergent adverse events (TEAEs) were reported in 148 (65.8%) patients, 95 (42.2%) were grade 3 or higher. The most common grade ≥3 TEAEs were anemia, thrombocytopenia, and neutropenia. Fifteen deaths (6.7%) occurred due to TEAEs during the study. Treatment is ongoing in 121 (53.8%) patients.

Conclusion
The interim results of this first, prospective study of real-life standard of care treatment demonstrate that heavily pretreated, triple-class exposed patients with relapsed/refractory MM continue to progress after multiple lines of therapy and have poor outcomes. Therefore, new treatments with novel mechanisms of action are needed for this patient population.

Keyword(s): Multiple myeloma, Refractory, Relapse, Treatment

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies